PMADS

Id:	acc1429
Group:	2sens
Protein:	HSP27
Gene Symbol:	HSPB1
Protein Id:	P04792
Protein Name:	HSPB1_HUMAN
PTM:	phosphorylation
Site:	Ser82
Site Sequence:	YSRALSRQLSSGVSEIRHTAD
Disease Category:	Cancer
Disease:	Lung Cancer
Disease Subtype:	NSCLC
Disease Cellline:	H1299
Disease Info:
Drug:	ZNF323A OV
Drug Info:	-
Effect:	modulate
Effect Info:	Drugs induce protein phosphorylation and promote tumor autophagy.
Note:	Non-conventional drugs
Score:	3.0
Pubmed(PMID):	32576196
Sentence Index:	32576196_6-7
Sentence:	"Thus, we further investigated the molecular regulation of ZNF322A, and found the inhibitory transcriptional regulation of ZNF322A on PIM3, which was able to phosphorylate IRS1 at serine1101 in order to manipulate glucose uptake via the PI3K/AKT/mTOR signaling pathway. Moreover, ZNF322A also affects the unfolded protein response by phosphorylation of HSP27S82 and eIF2aS51, and triggers autophagosome formation in lung cancer cells."

Sequence & Structure:

MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
HSPB1	APATORSEN	Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor	2	Unknown status	squamous cell lung carcinoma	ClinicalTrials
HSPB1	APATORSEN	Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor	2	Completed	pancreatic carcinoma	ClinicalTrials
HSPB1	APATORSEN	Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor	2	Completed	non-small cell lung carcinoma	ClinicalTrials
HSPB1	APATORSEN	Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor	2	Completed	prostate cancer	ClinicalTrials
HSPB1	APATORSEN	Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor	2	Terminated	prostate cancer	ClinicalTrials
HSPB1	APATORSEN	Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor	1	Completed	neoplasm	ClinicalTrials
HSPB1	APATORSEN	Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor	1	Unknown status	urinary bladder cancer	ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

HSPB1-Ser82
Cancer	Intensity
BRCA	0.019
COAD	-0.059
HGSC	2.597
ccRCC	-0.808
GBM	0.039
HNSC	0.23
LUAD	0.195
LUSC	-0.149
non_ccRCC	-1.441
PDAC	0.017
UCEC	-0.639

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
S	82	D	Atherosclerosis	Phosphorylation	15249501
S	82	N	Dilated cardiomyopathy	Phosphorylation	34477462
S	82	P	Pancreatic cancer/carcinoma/adenocarcinoma	Phosphorylation	22012255
S	82	U	Esophageal squamous cell carcinoma	Phosphorylation	32677057
S	82	U	Head and neck squamous cell carcinoma	Phosphorylation	34498800

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

Protein	Gene	PTM	Position	Modified sequence	Cell	Drug	pEC50	Regulation
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Dactolisib	6.0605	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	HeLa	CUDC101	3.3284	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	HeLa	Curcumin	4.2529	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	8.3757	up
P04792	HSPB1	P	Ser82;Ser83	QLS(ph)S(ph)GVSEIR	RPMI8226	BTZ	7.8377	up
P04792	HSPB1	P	Ser82;Ser83	QLS(ph)S(ph)GVSEIR	RPMI8226	BTZ	7.1638	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	7.0889	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	8.0294	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	7.8861	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	7.2749	up
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Dasatinib	6.352	down
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIRHTADRWR	RPMI8226	BTZ	9.6373	down
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Dasatinib	6.3955	down
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	MDA-MB-175	Lapatinib	5.6677	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	MDA-MB-175	Trastuzumab	-0.9329	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	KYSE-520	SHP099	6.5541	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Paclitaxel	8.2867	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Imatinib	5.7884	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Dasatinib	4	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Dasatinib	7.9911	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Dasatinib	7.5238	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Dasatinib	11.0131	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Dasatinib	8.9899	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Dasatinib	9.0111	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	K562	Cytarabine	6.6059	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	HeLa	SAHA	8.5519	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	HeLa	Romidepsin	8.2438	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	SK-BR-3	Pertuzumab	-0.9156	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	SK-BR-3	Trastuzumab	1.7802	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	SK-BR-3	Lapatinib	8.341	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIRHTADRWR	RPMI8226	BTZ	8.7691	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	5.9103	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	7.9042	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	8.771	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIRHTADRWR	RPMI8226	BTZ	10.1229	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	10.1272	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIRHTADRWR	RPMI8226	BTZ	8.141	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	RPMI8226	BTZ	7.765	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	MDA-MB-175	Pertuzumab	-3.7394	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	PC-9	LapatinibAZD4547	5.4968	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	PC-9	Lapatinib	7.255	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	PC-9	GeftinibAZD4547-1to80	7.8884	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	HeLa	A485	12.5732	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	PC-9	AZD4547	5.5413	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	PC-9	AZD4547	7.7593	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIRHTADRWR	MDA-MB-175	Pertuzumab	-3.9966	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Dasatinib	4.225	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A459	SelumetinibMK2206-3to1	7.745	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A459	SelumetinibMK2206-1to2	9.4222	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A459	Selumetinib	5.5528	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A459	MK2206	7.0597	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Imatinib	5.9678	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Gefitinib	13.3135	-
P04792	HSPB1	P	Ser82;Ser86	QLS(ph)SGVS(ph)EIR	A431	Gefitinib	5.791	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Gefitinib	16.5229	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Gefitinib	7.0041	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Gefitinib	2.6993	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	AZD8055	6.6691	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Dasatinib	7.1385	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Dasatinib	6.1741	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Dasatinib	3.7505	-
P04792	HSPB1	P	Ser82;Ser86	QLS(ph)SGVS(ph)EIR	A431	Dasatinib	5.9775	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Dasatinib	6.1537	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Afatinib	6.0243	-
P04792	HSPB1	P	Ser82;Ser86	QLS(ph)SGVS(ph)EIR	A431	Afatinib	16.5229	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Afatinib	4.4685	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Afatinib	6.088	-
P04792	HSPB1	P	Ser82;Ser86	QLS(ph)SGVS(ph)EIR	A431	Afatinib	6.9153	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-1.2345	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A431	Afatinib	4.5681	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	BT-474	Trastuzumab	-2.5813	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	BT-474	Pertuzumab	-1.1354	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	BT-474	Lapatinib	6.7023	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-3.6695	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-3.9794	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-3.6515	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-1.2236	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-3.7654	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-1.1318	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	HeLa	A486	5.2855	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	ARH-77	Rituximab	-1.6506	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Tideglusib	2	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Staursporin	7.7985	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Refametinib	7.1732	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Pictilisib	5.8355	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	PD325901	8.4449	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	PD325901	8.4574	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Nintedanib	6.6242	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	MK2206	6.9052	-
P04792	HSPB1	P	Ser82	QLS(ph)SGVSEIR	A549	Dasatinib	6.4872	-

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb